OncoMatch/Clinical Trials/NCT06693973
An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Is NCT06693973 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies AcNK-Sup003 cell for b-cell non-hodgkin lymphoma (b-nhl).
Treatment: AcNK-Sup003 cell — The purpose of this study is to determine whether AcNK-Sup003 cell injection is safe and effective in the treatment of elapsed or refractory B-cell non-Hodgkin's lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 overexpression (CD20+)
Confirmed by pathology to have CD20+ relapsed or refractory B-cell non-Hodgkin's lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: CD20-targeted therapy — second-line or later
must have received CD20-targeted drugs [excluding CD20-negative tumors]
Must have received: anthracycline — second-line or later
must have received...anthracycline drugs
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: within 3 months before lymphodepletion
Received autologous hematopoietic stem cell transplantation or other autologous cell therapy products within 3 months before lymphodepletion
Cannot have received: allogeneic hematopoietic stem cell transplantation
Exception: within 6 months before lymphodepletion
received allogeneic hematopoietic stem cell transplantation or other allogeneic cell therapy products within 6 months before lymphodepletion
Cannot have received: other organ transplant
subjects who have undergone other organ transplants
Cannot have received: anti-tumor drug treatment
Exception: within 4 weeks before lymphodepletion or within 5 half-lives (whichever is shorter)
Received anti-tumor drug treatment or participated in other interventional clinical studies within 4 weeks before lymphodepletion or within 5 half-lives (whichever is shorter), including but not limited to chemotherapy drugs, small molecule targeted drugs, monoclonal antibodies, antibody-drug conjugates, etc.
Lab requirements
Blood counts
Hemoglobin (Hb) ≥80 g/L, ANC ≥1×10^9/L, Platelet Count (PLT) ≥50×10^9/L
Kidney function
Serum creatinine ≤1.5×ULN, or creatinine clearance ≥50 mL/min (Cockcroft-Gault)
Liver function
Total bilirubin ≤1.5×ULN (≤3×ULN for subjects with liver lesions or Gilbert's syndrome); ALT and AST ≤3×ULN (≤5×ULN for subjects with liver lesions)
Cardiac function
QTcF ≤450 ms (males), ≤470 ms (females); LVEF ≥50%; NYHA <II; no serious arrhythmias, acute coronary syndrome, or grade 3+ cardiovascular/cerebrovascular events within 6 months; controlled blood pressure
Hematological parameters...Coagulation function...Hepatic, renal, and pulmonary function must meet the following requirements
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06693973 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous hematopoietic stem cell transplantation, allogeneic hematopoietic stem cell transplantation, other organ transplant disqualifies patients from enrollment.
Does this trial require MS4A1?
Yes, MS4A1 overexpression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages